Merck & Company Inc (MRK)vsNexgel Inc (NXGL)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NXGL
Nexgel Inc
$0.29
+0.34%
HEALTHCARE · Cap: $3.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 551562% more annual revenue ($66.57B vs $12.07M). MRK leads profitability with a 4.8% profit margin vs -51.3%. NXGL earns a higher WallStSmart Score of 39/100 (F).
MRK
Hold36
out of 100
Grade: F
NXGL
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+43.8%
Fair Value
$2.49
Current Price
$0.29
$2.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 27.8% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -80.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NXGL
The strongest argument for NXGL centers on Price/Book, Revenue Growth. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NXGL
The primary concerns for NXGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.51 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while NXGL is a growth play — different risk/reward profiles.
NXGL carries more volatility with a beta of 0.75 — expect wider price swings.
NXGL is growing revenue faster at 27.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NXGL scores higher overall (39/100 vs 36/100) and 27.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nexgel Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?